

**F-STAR THERAPEUTICS, INC.**  
**Eddeva B920**  
**Babraham Research Campus**  
**Cambridge, CB22 3AT, United Kingdom**

August 19, 2021

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: David Gessert

**RE: F-star Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed August 13, 2021**  
**File No. 333-258783**  
**Acceleration Request**

Dear Mr. Gessert:

With respect to the above-referenced Registration Statement on Form S-3 (the "Registration Statement"), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of F-star Therapeutics, Inc. (the "Company"), that the Securities and Exchange Commission (the "Commission") accelerate the effective date of the Registration Statement to Monday, August 23, 2021, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Megan Gates or William Hicks of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.

Very truly yours,

F-STAR THERAPEUTICS, INC.

/s/ Darlene Deptula-Hicks

Darlene Deptula-Hicks  
Chief Financial Officer

cc: Megan N. Gates, Esq., *Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.*  
William C. Hicks, Esq., *Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.*